Alnylam Pharmace. buy tamam
Start price
20.09.17
/
50%
€87.81
Target price
20.09.17
€76.67
Performance (%)
7.87%
End price
20.09.17
€94.72
Summary
This prediction ended on 20.09.17 with a price of €94.72. The BUY prediction by tamam finished with a performance of 7.87%. tamam has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 0.207% | 0.207% | 49.978% | 52.613% |
| iShares Core DAX® | 0.794% | 2.841% | 22.630% | 72.985% |
| iShares Nasdaq 100 | 0.016% | -0.939% | 6.943% | 115.777% |
| iShares Nikkei 225® | 0.309% | -0.648% | 13.619% | 49.561% |
| iShares S&P 500 | 0.181% | -0.442% | 4.692% | 69.577% |
Comments by tamam for this prediction
In the thread Alnylam Pharmace. diskutieren
tamam stimmt der Buy-Einschätzung von melinda zu
tamam stimmt am 20.09.2017 der Buy-Einschätzung von melinda mit dem Kursziel 85$ zu.
Überschrift: pharma